Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction therapy with rituximab + Hyper-CVAD and high-dose methotrexate/cytarabine followed by Y90-ibritumomab tiuxetan consolidation in mantle cell lymphoma
2005-004400-37Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Dec 2005
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in mantle cell lymphoma (MCL), sponsored by GELTAMO. Primary endpoints: Safety profile of the treatment regimen and Feasibility of the treatment regimen. Started Dec 2005; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2005-004400-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004400-37.